Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor.

Vasiljevic S, Beale EV, Bonomelli C, Easthope IS, Pritchard LK, Seabright GE, Caputo AT, Scanlan CN, Dalziel M, Crispin M.

Mol Immunol. 2015 Dec;68(2 Pt A):234-43. doi: 10.1016/j.molimm.2015.08.014. Epub 2015 Sep 29.

PMID:
26391350
2.

Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies.

Pritchard LK, Spencer DI, Royle L, Bonomelli C, Seabright GE, Behrens AJ, Kulp DW, Menis S, Krumm SA, Dunlop DC, Crispin DJ, Bowden TA, Scanlan CN, Ward AB, Schief WR, Doores KJ, Crispin M.

Nat Commun. 2015 Jun 24;6:7479. doi: 10.1038/ncomms8479.

3.

Fragments of bacterial endoglycosidase s and immunoglobulin g reveal subdomains of each that contribute to deglycosylation.

Dixon EV, Claridge JK, Harvey DJ, Baruah K, Yu X, Vesiljevic S, Mattick S, Pritchard LK, Krishna B, Scanlan CN, Schnell JR, Higgins MK, Zitzmann N, Crispin M.

J Biol Chem. 2014 May 16;289(20):13876-89. doi: 10.1074/jbc.M113.532812. Epub 2014 Mar 25.

4.

Emerging principles for the therapeutic exploitation of glycosylation.

Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA.

Science. 2014 Jan 3;343(6166):1235681. doi: 10.1126/science.1235681. Review.

PMID:
24385630
5.

Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies.

Yu X, Baruah K, Harvey DJ, Vasiljevic S, Alonzi DS, Song BD, Higgins MK, Bowden TA, Scanlan CN, Crispin M.

J Am Chem Soc. 2013 Jul 3;135(26):9723-32. doi: 10.1021/ja4014375. Epub 2013 Jun 25.

6.

Travelling wave ion mobility and negative ion fragmentation for the structural determination of N-linked glycans.

Harvey DJ, Scarff CA, Edgeworth M, Crispin M, Scanlan CN, Sobott F, Allman S, Baruah K, Pritchard L, Scrivens JH.

Electrophoresis. 2013 Aug;34(16):2368-78. doi: 10.1002/elps.201200669. Epub 2013 Jul 22.

PMID:
23712623
7.

Impact of immune complex size and glycosylation on IgG binding to human FcγRs.

Lux A, Yu X, Scanlan CN, Nimmerjahn F.

J Immunol. 2013 Apr 15;190(8):4315-23. doi: 10.4049/jimmunol.1200501. Epub 2013 Mar 18.

8.

Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain.

Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN.

J Mol Biol. 2013 Apr 26;425(8):1253-8. doi: 10.1016/j.jmb.2013.02.006. Epub 2013 Feb 13.

PMID:
23416198
9.

A Blueprint for HIV Vaccine Discovery.

Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R.

Cell Host Microbe. 2012 Oct 18;12(4):396-407. doi: 10.1016/j.chom.2012.09.008. Review.

10.

Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis.

Bowden TA, Baruah K, Coles CH, Harvey DJ, Yu X, Song BD, Stuart DI, Aricescu AR, Scanlan CN, Jones EY, Crispin M.

J Am Chem Soc. 2012 Oct 24;134(42):17554-63. doi: 10.1021/ja306068g. Epub 2012 Oct 15.

11.

MALDI-MS/MS with traveling wave ion mobility for the structural analysis of N-linked glycans.

Harvey DJ, Scarff CA, Crispin M, Scanlan CN, Bonomelli C, Scrivens JH.

J Am Soc Mass Spectrom. 2012 Nov;23(11):1955-66. doi: 10.1007/s13361-012-0425-8. Epub 2012 Sep 20.

PMID:
22993039
12.

An endoglycosidase with alternative glycan specificity allows broadened glycoprotein remodelling.

Goodfellow JJ, Baruah K, Yamamoto K, Bonomelli C, Krishna B, Harvey DJ, Crispin M, Scanlan CN, Davis BG.

J Am Chem Soc. 2012 May 16;134(19):8030-3. doi: 10.1021/ja301334b. Epub 2012 May 2.

PMID:
22551167
13.

Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions.

Baruah K, Bowden TA, Krishna BA, Dwek RA, Crispin M, Scanlan CN.

J Mol Biol. 2012 Jun 29;420(1-2):1-7. doi: 10.1016/j.jmb.2012.04.002. Epub 2012 Apr 5.

14.

A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.

Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA.

Science. 2011 Nov 25;334(6059):1097-103. doi: 10.1126/science.1213256. Epub 2011 Oct 13.

15.

The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade.

Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M, Scanlan CN.

PLoS One. 2011;6(8):e23521. doi: 10.1371/journal.pone.0023521. Epub 2011 Aug 16.

16.

Use of the α-mannosidase I inhibitor kifunensine allows the crystallization of apo CTLA-4 homodimer produced in long-term cultures of Chinese hamster ovary cells.

Yu C, Crispin M, Sonnen AF, Harvey DJ, Chang VT, Evans EJ, Scanlan CN, Stuart DI, Gilbert RJ, Davis SJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Jul 1;67(Pt 7):785-9. doi: 10.1107/S1744309111017672. Epub 2011 Jun 30.

17.

Ion mobility mass spectrometry for extracting spectra of N-glycans directly from incubation mixtures following glycan release: application to glycans from engineered glycoforms of intact, folded HIV gp120.

Harvey DJ, Sobott F, Crispin M, Wrobel A, Bonomelli C, Vasiljevic S, Scanlan CN, Scarff CA, Thalassinos K, Scrivens JH.

J Am Soc Mass Spectrom. 2011 Mar;22(3):568-81. doi: 10.1007/s13361-010-0053-0. Epub 2011 Feb 8.

PMID:
21472575
18.

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity.

Doores KJ, Fulton Z, Hong V, Patel MK, Scanlan CN, Wormald MR, Finn MG, Burton DR, Wilson IA, Davis BG.

Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17107-12. doi: 10.1073/pnas.1002717107. Epub 2010 Sep 17.

19.

Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity.

Kong L, Sheppard NC, Stewart-Jones GBE, Robson CL, Chen H, Xu X, Krashias G, Bonomelli C, Scanlan CN, Kwong PD, Jeffs SA, Jones IM, Sattentau QJ.

J Mol Biol. 2010 Oct 15;403(1):131-147. doi: 10.1016/j.jmb.2010.08.033. Epub 2010 Aug 25.

20.

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13800-5. doi: 10.1073/pnas.1006498107. Epub 2010 Jul 19.

21.

Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans.

Dunlop DC, Bonomelli C, Mansab F, Vasiljevic S, Doores KJ, Wormald MR, Palma AS, Feizi T, Harvey DJ, Dwek RA, Crispin M, Scanlan CN.

Glycobiology. 2010 Jul;20(7):812-23. doi: 10.1093/glycob/cwq020. Epub 2010 Feb 24.

22.

Antigenic mimicry of the HIV envelope by AIDS-associated pathogens.

Dunlop DC, Ulrich A, Appelmelk BJ, Burton DR, Dwek RA, Zitzmann N, Scanlan CN.

AIDS. 2008 Oct 18;22(16):2214-7. doi: 10.1097/QAD.0b013e328314b5df.

PMID:
18832887
23.

Application of negative ion MS/MS to the identification of N-glycans released from carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1).

Harvey DJ, Baruah K, Scanlan CN.

J Mass Spectrom. 2009 Jan;44(1):50-60. doi: 10.1002/jms.1470.

PMID:
18788072
24.

A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.

Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, Blixt O, Dwek RA, Wong CH, Burton DR.

J Virol. 2008 Jul;82(13):6359-68. doi: 10.1128/JVI.00293-08. Epub 2008 Apr 23.

25.

Making autoantibodies safe.

Scanlan CN, Burton DR, Dwek RA.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4081-2. doi: 10.1073/pnas.0801192105. Epub 2008 Mar 14. No abstract available.

26.

A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120.

Menendez A, Calarese DA, Stanfield RL, Chow KC, Scanlan CN, Kunert R, Katinger H, Burton DR, Wilson IA, Scott JK.

FASEB J. 2008 May;22(5):1380-92. doi: 10.1096/fj.07-8983com. Epub 2008 Jan 15.

27.

Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody.

Scanlan CN, Ritchie GE, Baruah K, Crispin M, Harvey DJ, Singer BB, Lucka L, Wormald MR, Wentworth P Jr, Zitzmann N, Rudd PM, Burton DR, Dwek RA.

J Mol Biol. 2007 Sep 7;372(1):16-22. Epub 2007 Jun 16.

PMID:
17631311
28.

Exploiting the defensive sugars of HIV-1 for drug and vaccine design.

Scanlan CN, Offer J, Zitzmann N, Dwek RA.

Nature. 2007 Apr 26;446(7139):1038-45. Review.

PMID:
17460665
29.

Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.

Lee HK, Scanlan CN, Huang CY, Chang AY, Calarese DA, Dwek RA, Rudd PM, Burton DR, Wilson IA, Wong CH.

Angew Chem Int Ed Engl. 2004 Feb 13;43(8):1000-3. No abstract available.

PMID:
14966891
30.

The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12.

Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Calarese D, Stanfield R, Wilson IA, Katinger H, Dwek RA, Burton DR, Rudd PM.

Adv Exp Med Biol. 2003;535:205-18. No abstract available.

PMID:
14714897
31.

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA.

Science. 2003 Jun 27;300(5628):2065-71.

32.

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR.

J Virol. 2002 Jul;76(14):7306-21.

Supplemental Content

Loading ...
Support Center